| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
|
Lancet Oncol
|
2009
|
8.68
|
|
2
|
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
|
N Engl J Med
|
2015
|
7.51
|
|
3
|
Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response.
|
Proc Natl Acad Sci U S A
|
2001
|
3.29
|
|
4
|
Role of PFKFB3-driven glycolysis in vessel sprouting.
|
Cell
|
2013
|
3.04
|
|
5
|
Mouse fibroblasts lacking RB1 function form spheres and undergo reprogramming to a cancer stem cell phenotype.
|
Cell Stem Cell
|
2009
|
2.00
|
|
6
|
Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer.
|
Exp Mol Pathol
|
2009
|
1.92
|
|
7
|
Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth.
|
Mol Cancer Ther
|
2008
|
1.89
|
|
8
|
High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers.
|
Cancer Res
|
2002
|
1.84
|
|
9
|
Targeting aspartate aminotransferase in breast cancer.
|
Breast Cancer Res
|
2008
|
1.78
|
|
10
|
Transient T cell depletion causes regression of melanoma metastases.
|
J Transl Med
|
2008
|
1.61
|
|
11
|
The oncoprotein H-RasV12 increases mitochondrial metabolism.
|
Mol Cancer
|
2007
|
1.33
|
|
12
|
Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases.
|
J Biol Chem
|
2009
|
1.27
|
|
13
|
Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.
|
Mol Cancer Ther
|
2013
|
1.19
|
|
14
|
Disruption of inducible 6-phosphofructo-2-kinase ameliorates diet-induced adiposity but exacerbates systemic insulin resistance and adipose tissue inflammatory response.
|
J Biol Chem
|
2009
|
1.14
|
|
15
|
Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma.
|
Clin Cancer Res
|
2011
|
1.13
|
|
16
|
Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation.
|
J Transl Med
|
2012
|
1.13
|
|
17
|
Depletion of ascorbic acid restricts angiogenesis and retards tumor growth in a mouse model.
|
Neoplasia
|
2007
|
0.97
|
|
18
|
Molecular pathways: regulation of metabolism by RB.
|
Clin Cancer Res
|
2012
|
0.92
|
|
19
|
Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma.
|
BMC Cancer
|
2011
|
0.91
|
|
20
|
The ZEB1 transcription factor acts in a negative feedback loop with miR200 downstream of Ras and Rb1 to regulate Bmi1 expression.
|
J Biol Chem
|
2013
|
0.87
|
|
21
|
Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma.
|
Drugs
|
2011
|
0.86
|
|
22
|
Sequential inductions of the ZEB1 transcription factor caused by mutation of Rb and then Ras proteins are required for tumor initiation and progression.
|
J Biol Chem
|
2013
|
0.84
|
|
23
|
Emerging strategies in regulatory T-cell immunotherapies.
|
Clin Adv Hematol Oncol
|
2009
|
0.83
|
|
24
|
Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3).
|
J Biol Chem
|
2014
|
0.83
|
|
25
|
Virus detection and identification using random multiplex (RT)-PCR with 3'-locked random primers.
|
Virol J
|
2007
|
0.82
|
|
26
|
The Rb/E2F pathway and Ras activation regulate RecQ helicase gene expression.
|
Biochem J
|
2008
|
0.82
|
|
27
|
Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth.
|
Mol Cancer
|
2012
|
0.81
|
|
28
|
Rb1 family mutation is sufficient for sarcoma initiation.
|
Nat Commun
|
2013
|
0.79
|
|
29
|
Cloning and chromosomal characterization of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 gene (PFKFB3, iPFK2).
|
Int J Oncol
|
2003
|
0.78
|
|
30
|
Block copolymer micelles for controlled delivery of glycolytic enzyme inhibitors.
|
Pharm Res
|
2011
|
0.77
|
|
31
|
Immunotherapy: Tumor-infiltrating T cells--ready for prime time in melanoma?
|
Nat Rev Clin Oncol
|
2011
|
0.75
|
|
32
|
Erratum: Different thresholds of ZEB1 are required for Ras-mediated tumour initiation and metastasis.
|
Nat Commun
|
2015
|
0.75
|